Generic Mozobil Availability
Last updated on Jun 11, 2025.
Mozobil is a brand name of plerixafor, approved by the FDA in the following formulation(s):
MOZOBIL (plerixafor - solution;subcutaneous)
Is there a generic version of Mozobil available?
Yes. The following products are equivalent to Mozobil:
plerixafor solution;subcutaneous
-
Manufacturer: AMNEAL
Approval date: July 24, 2023
Strength(s): 24MG/1.2ML (20MG/ML) [AP] -
Manufacturer: DR REDDYS
Approval date: July 24, 2023
Strength(s): 24MG/1.2ML (20MG/ML) [AP] -
Manufacturer: EUGIA PHARMA
Approval date: July 24, 2023
Strength(s): 24MG/1.2ML (20MG/ML) [AP] -
Manufacturer: GLAND
Approval date: May 3, 2024
Strength(s): 24MG/1.2ML (20MG/ML) [AP] -
Manufacturer: MEITHEAL
Approval date: July 24, 2023
Strength(s): 24MG/1.2ML (20MG/ML) [AP] -
Manufacturer: MSN
Approval date: July 24, 2023
Strength(s): 24MG/1.2ML (20MG/ML) [AP] -
Manufacturer: TEVA PHARMS USA INC
Approval date: July 24, 2023
Strength(s): 24MG/1.2ML (20MG/ML) [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mozobil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Mozobil (plerixafor)
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: hematopoietic stem cell mobilizer
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Darzalex
Darzalex (daratumumab) is a prescription medicine used to treat multiple myeloma. Includes Darzalex ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
Pomalyst
Pomalyst (pomalidomide) is used to treat multiple myeloma and AIDS-related Kaposi sarcoma. Includes ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.